Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ardelyx, Inc. ARDX
$4.27
-$0.02 (-0.47%)
На 18:00, 12 мая 2023
+5.39%
Потенциал через год
Ранг: 1
Ключевые показатели
-
Marketcap
923258910.00000000
-
week52high
5.13
-
week52low
0.49
-
Revenue
52158000
-
P/E TTM
-13
-
Beta
1.17404800
-
EPS
-0.41000000
-
Last Dividend
0.00000000
-
Next Earnings Date
03 мая 2023 г. в 20:02
Описание компании
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Neutral | Neutral | 19 мая 2022 г. |
| Cantor Fitzgerald | Neutral | Overweight | 06 мая 2022 г. |
| Jefferies | Buy | Hold | 02 мар 2022 г. |
| Ladenburg Thalmann | Buy | Neutral | 01 дек 2021 г. |
| Citigroup | Buy | Buy | 01 дек 2021 г. |
| Piper Sandler | Overweight | Neutral | 17 ноя 2022 г. |
| Citigroup | Buy | Buy | 30 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Felsch Robert Ora | A | 120000 | 120000 | 05 янв 2023 г. |
| Felsch Robert Ora | A | 117418 | 26000 | 05 янв 2023 г. |
| Rosenbaum David P. | A | 116250 | 116250 | 05 янв 2023 г. |
| Rosenbaum David P. | A | 351000 | 351000 | 05 янв 2023 г. |
| Rosenbaum David P. | A | 114210 | 25325 | 05 янв 2023 г. |
| Rosenbaum David P. | A | 378994 | 78000 | 05 янв 2023 г. |
| RAAB MICHAEL | A | 1124000 | 1124000 | 05 янв 2023 г. |
| RAAB MICHAEL | A | 909461 | 250000 | 05 янв 2023 г. |
| Williams Laura A | A | 351000 | 351000 | 05 янв 2023 г. |
| Williams Laura A | A | 322200 | 78000 | 05 янв 2023 г. |
Новостная лента
Ardelyx, Inc. (ARDX) Q1 2023 Earnings Call Transcript
Seeking Alpha
03 мая 2023 г. в 22:51
Ardelyx, Inc. (NASDAQ:ARDX ) Q1 2023 Results Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Caitlin Lowie - Vice President, Corporate Communications and Investor Relations Mike Raab - President and Chief Executive Officer Susan Rodriguez - Chief Commercial Officer Justin Renz - Chief Financial and Operations Officer Conference Call Participants Yigal Nochomovitz - Citi Research Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Christopher Raymond - Piper Sandler & Co. Matthew Kaplan - Ladenburg Thalmann Operator Good day. And welcome to the Ardelyx First Quarter 2023 Conference Call.
Ardelyx (ARDX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
03 мая 2023 г. в 19:02
Ardelyx (ARDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.21 per share a year ago.
Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023
GlobeNewsWire
26 апр 2023 г. в 08:00
WALTHAM, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Wednesday, May 3, 2023, at 4:30 p.m.
Ardelyx: Underappreciated Biotech With Potential FDA Approval On Deck
Seeking Alpha
24 апр 2023 г. в 03:34
Ardelyx: Underappreciated Biotech With Potential FDA Approval On Deck.
Top Penny Stocks To Buy Now? 10 To Watch Under $5
PennyStocks
13 апр 2023 г. в 11:27
10 Penny stocks under $5 to watch right now The post Top Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.